- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- Ciclesonide, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 153
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
- Interventions
- Not listed
- Lead sponsor
- Global Healthy Living Foundation
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 40,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Upper Nyack, New York
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose), placebo to tiotropium+olodaterol
- Device · Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 15
- States / cities
- Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more
- Conditions
- PAH
- Interventions
- oral treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 9
- States / cities
- Palo Alto, California • San Francisco, California • Aurora, Colorado + 6 more
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Auto-titrating mandibular positioner test
- Device
- Lead sponsor
- Zephyr Sleep Technologies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Bellevue, Washington
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Beraprost Sodium 314d Modified Release Tablets, Placebo
- Drug
- Lead sponsor
- Lung Biotechnology PBC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 55 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- tiotropium + olodaterol, tiotropium, olodaterol, Placebo, Respimat
- Drug · Device
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- Jasper, Alabama • Easley, South Carolina • Greenville, South Carolina + 1 more
- Conditions
- Pulmonary Arterial Hypertension (PAH)
- Interventions
- LIQ861 (treprostinil) inhalation powder
- Combination Product
- Lead sponsor
- Liquidia Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Georgia
- Conditions
- Diabetes Mellitus
- Interventions
- Inhaled Insulin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 18
- States / cities
- La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Not listed
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Type 2 Diabetes
- Interventions
- Technosphere® Insulin, Technosphere Powder
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 50
- States / cities
- Anaheim, California • Huntington Beach, California • Laguna Hills, California + 41 more
- Conditions
- Obstructive Sleep Apnea
- Interventions
- EVO Sleep and Snore Device
- Device
- Lead sponsor
- ProSomnus Sleep Technologies
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- New York, New York • Dallas, Texas
- Conditions
- Croup
- Interventions
- Fluticasone, Prednisolone IF needed
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 6 Months to 15 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Narcolepsy, Obstructive Sleep Apnea, Excessive Daytime Somnolence, Excessive Sleepiness, Postpartum
- Interventions
- Solriamfetol 150 mg Oral Tablet
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Raleigh, North Carolina
- Conditions
- Asthma
- Interventions
- QGE031, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Kingwood, Texas • Plano, Texas
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Seralutinib, Gereic Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- Gossamer Bio USA, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 33
- States / cities
- Fresno, California • Los Angeles, California • Sacramento, California + 26 more
- Conditions
- Cystic Fibrosis
- Interventions
- azithromycin, placebo (for azithromycin), inhaled tobramycin
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 39
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 33 more
- Conditions
- Asthma
- Interventions
- Benralizumab
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 598 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 23
- States / cities
- Flagstaff, Arizona • Los Angeles, California • Aurora, Colorado + 20 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin glargine, Inhaled Insulin (Exubera)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 72
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Concord, California + 63 more
- Conditions
- Asthma
- Interventions
- Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 5 Years to 9 Years
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more
- Conditions
- Obstructive Sleep Apnea (OSA), Oral Applliance Therapy
- Interventions
- The study will assess the feasibility of incorporating the PLATO questionnaire into a dental sleep practice. The PLATO questionnaire was developed as a patient reported outcome measure
- Other
- Lead sponsor
- Nevada Dental Sleep
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Henderson, Nevada
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2
- Interventions
- Aerolized Hydroxychloroquine Sulfate, Placebo
- Drug · Other
- Lead sponsor
- Pulmoquine Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Oral Bacterial Infection, Mechanical Ventilation Complication
- Interventions
- SwishKit + Oral care treatment as usual, Oral care treatment as usual
- Device · Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio